CN113045530A - 一种钌催化制备萘并吡喃类化合物的方法 - Google Patents

一种钌催化制备萘并吡喃类化合物的方法 Download PDF

Info

Publication number
CN113045530A
CN113045530A CN202110309305.0A CN202110309305A CN113045530A CN 113045530 A CN113045530 A CN 113045530A CN 202110309305 A CN202110309305 A CN 202110309305A CN 113045530 A CN113045530 A CN 113045530A
Authority
CN
China
Prior art keywords
unsubstituted
substituted
alkyl
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110309305.0A
Other languages
English (en)
Other versions
CN113045530B (zh
Inventor
李喆宇
李知仪
马文博
辜玲慧
谭玉强
唐克慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu University
Original Assignee
Chengdu University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu University filed Critical Chengdu University
Priority to CN202110309305.0A priority Critical patent/CN113045530B/zh
Publication of CN113045530A publication Critical patent/CN113045530A/zh
Application granted granted Critical
Publication of CN113045530B publication Critical patent/CN113045530B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/92Naphthopyrans; Hydrogenated naphthopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种钌催化制备萘并吡喃类化合物的方法,在惰性气体和/或氮气气氛下,将化合物1、化合物2、钌催化剂、添加剂、碱、溶剂混合反应后,直接反应体系中添加三氟甲磺酸酐反应后即得。本发明方法通过一锅法制备萘并吡喃类化合物反应步骤短,操作简单,高效快捷,同时反应条件缓和,底物耐受性较好,适用范围广泛,解决了传统反应条件苛刻,操作复杂,底物局限,步骤繁琐,底物的官能团不耐受等不足,实现了萘酚C8位选择性酰甲基化以及环化反应制备萘并吡喃类化合物,为药物以及光电材料的开发奠定基础。

Description

一种钌催化制备萘并吡喃类化合物的方法
技术领域
本发明涉及有机合成领域,特别是涉及一种钌催化制备萘并吡喃类化合物的方法。
背景技术
萘并吡喃类结构广泛的存在于具有生物活性的天然产物,药物分子或者光电子能性材料中。因此对于此类化合物的合成与结构修饰一直是化学工作者关注的重点。传统的合成方法大都以预官能化的萘酚为起始原料,经过氧化,还原,环合等反应,反应路线较长反应条件苛刻官能团耐受性较差,产物的多样性极大的受到了限制。
近年来,过渡金属催化的选择性C-H官能团化已经成为生物活性分子合成或结构修饰的重要策略。然而,关于过渡金属催化的合成萘酚合成芳并吡喃类化合物的研究仅仅局限于萘酚与炔类底物的环合反应。在2010年,Miura课题组报道了第一例Rh(III)催化的萘酚与炔类化合物的环化反应,此反应催化剂过渡金属铑价格昂贵。在此基础上,Ackermann和Sen课题组利用廉价的钌或者钴作为催化剂也顺利实现了萘酚类化合物与炔的环化反应。虽然这些反应为萘并吡喃类化合物的提供了一条经济便捷的合成路线,但是该类反应涉及使用加化学当量的金属铜盐作为氧化剂,对环境造成一定的重金属污染。最近Ackermann课题组在过渡金属钌催化下利用电合成技术实现了萘酚与炔的环化反应,此反应避免使用化学当量的铜盐作为氧化剂,更加符合绿色化学要求。
过渡金属催化萘酚与炔环化反应制备萘并吡喃类化合物取得了一定的进展,但是这些反应涉及的底物炔类化合物制备繁琐价格普遍昂贵,并且当反应底物为不对称炔时,反应的区域选择性较差,生成异构体难以分离。尤其是对于端炔类底物不适用,极大的限制了产物的多样性。
因此,发展一种反应条件缓和,高效便捷,底物耐受性较好,能够解决上述技术问题的的新合成方法显得十分必要。
发明内容
本发明解决的主要技术问题是提供一种钌催化制备萘并吡喃类化合物的方法,操作简单,底物范围广,实现了一系列萘并吡喃类化合物的高效合成。
为了解决上述的技术问题,本发明所采用的技术方案是:
本发明提供化合物3的制备方法,包含以下内容:在惰性气体和/或氮气气氛下,将化合物1、化合物2、钌催化剂、添加剂、碱、溶剂混合:
Figure BDA0002989134880000021
所述钌催化剂选自钌化合物和/或钌络合物;
所述添加剂选自铜盐或铜的氧化物;
R1选自非取代或取代的烷基、非取代或取代的杂烷基、非取代或取代的环烷基、非取代或取代的杂环烷基、非取代或取代的芳基、非取代或取代的杂芳基;
R3选自卤素、硝基、羟基、巯基、氨基、氰基、酰胺基、酰基、酯基、磺酰基、非取代或取代的烷基、非取代或取代的杂烷基、非取代或取代的环烷基、非取代或取代的杂环烷基、非取代或取代的芳基、非取代或取代的杂芳基;
R1、R3中的取代基选自卤素、硝基、羟基、巯基、氨基、氰基、酰胺基、酰基、酯基、磺酰基、烷基、杂烷基、环烷基、杂环烷基、芳基、杂芳基,或两个相邻的取代基共同组成非取代或取代的烷基、非取代或取代的杂烷基;
n选自0、1、2、3、4。
反应完后,通过本领域常规的后处理方法(过滤、浓缩、柱层析等)即可得到化合物3。
结构中虚线表示该部分结构可不存在。
进一步地,所述钌催化剂选自为[RuCl2(p-cymene)]2、CpRuCl(PPh3)2、RuCl3、RuCl2(PPh3)3中的一种或几种,优选[RuCl2(p-cymene)]2
进一步地,所述钌催化剂的摩尔用量为化合物1摩尔用量的1.0%~20.0%,优选1.0%~10.0%,优选2.0%~7.0%,更优选为5.0%。
进一步地,所述添加剂选自Cu(OAc)2、Cu(OAc)2·H2O、CuCl2、CuO、Cu2O中的一种或几种,优选Cu(OAc)2和/或Cu(OAc)2·H2O。
进一步地,所述添加剂的摩尔用量为化合物1摩尔用量的1.0%~20.0%,优选1.0%~10.0%,优选2.0%~7.0%,更优选为5.0%。
进一步地,所述碱选自无机碱;进一步地,所述碱选自KOAc、NaOAc、K2CO3、Na2CO3、Cs2CO3、KHCO3、NaHCO3、K3PO4、Na3PO4、K2HPO4、Na2HPO4、KH2PO4、NaH2PO4中的一种或几种,优选KOAc。
进一步地,所述碱的摩尔用量为化合物1摩尔用量的1~5倍,优选1~3倍,更优选为2倍。
进一步地,所述溶剂选自二氯甲烷、二氯乙烷、四氢呋喃、甲苯、三氟甲苯中的一种或几种,优选二氯甲烷。
进一步地,所述溶剂的用量为,化合物1:溶剂的料液比为1mmol:5~15mL,优选为1mmol:5~10mL,更优选为1mmol:8mL。
进一步地,所述反应的温度为80℃~120℃,优选100℃。
进一步地,所述化合物2的摩尔用量为化合物1摩尔用量的1~5倍,优选1~3倍,更优选为1.5倍。
进一步地,R1选自非取代或取代的C1~C12烷基、非取代或取代的2~11元杂烷基、非取代或取代的C1~C12环烷基、非取代或取代的2~11元杂环烷基、非取代或取代的6~10元芳基、非取代或取代的5~10元杂芳基;
R3选自卤素、硝基、羟基、氰基、酰胺基、酰基、酯基、非取代或取代的烷基、非取代或取代的杂烷基、非取代或取代的环烷基、非取代或取代的杂环烷基、非取代或取代的芳基、非取代或取代的杂芳基;
R1、R3中的取代基选自卤素、硝基、羟基、氨基、氰基、酰胺基、酰基、酯基、烷基、杂烷基、环烷基、杂环烷基、芳基、杂芳基,或两个相邻的取代基共同组成非取代或取代的烷基、非取代或取代的杂烷基;
进一步地,R1选自非取代或取代的C1~C6烷基、非取代或取代的2~5元杂烷基、非取代或取代的C1~C12环烷基、非取代或取代的2~11元杂环烷基、非取代或取代的6~10元芳基、非取代或取代的5元杂芳基;
R3选自卤素、非取代或取代的C1~C6烷基、非取代或取代的2~5元杂烷基、非取代或取代的C1~C6环烷基、非取代或取代的2~5元杂环烷基;
R1、R3中的取代基选自卤素、硝基、羟基、氨基、氰基、酰胺基、酰基、酯基、烷基、杂烷基、环烷基、杂环烷基、芳基、杂芳基,或两个相邻的取代基共同组成非取代或取代的烷基、非取代或取代的杂烷基;
进一步地,R1选自非取代或取代的C1~C6烷基、非取代或取代的C1~C12环烷基、非取代或取代的苯基、非取代或取代的萘基、非取代或取代的噻吩基、非取代或取代的呋喃基;
R3选自卤素、非取代或取代的C1~C6烷基;
R1、R3中的取代基选自卤素、硝基、氰基、烷基、烷氧基、芳基、烯基,或两个相邻的取代基共同组成非取代或取代的氧杂烷基;n选自0、1、2;
进一步地,R1选自非取代或取代的C1~C6烷基、非取代或取代的C1~C12环烷基、非取代或取代的苯基、非取代或取代的萘基、非取代或取代的噻吩基、非取代或取代的呋喃基;
R3选自卤素、非取代或取代的C1~C3烷基;
R1、R3中的取代基选自卤素、硝基、氰基、烷基、三氟甲基、烷氧基、苯基、乙烯基,或两个相邻的取代基共同组成非取代或取代的
Figure BDA0002989134880000041
n选自0、1;
更进一步地,所述R1选自如下基团:
Figure BDA0002989134880000042
R3选自Br、甲基。
本发明还提供了一种化合物4的制备方法:向上述任一化合物3的制备方法反应后的反应体系中加入三氟甲磺酸酐:
Figure BDA0002989134880000043
当需要制备化合物4时,可在制备化合物3的反应体系反应完后,直接加入三氟甲磺酸酐,无需单独分离纯化出化合物3,操作方便,简化了生产步骤。
进一步地,所述三氟甲磺酸酐的摩尔用量为化合物1摩尔用量的0.2~2倍,优选0.2~1倍,更优选为0.3~0.5倍。
在本发明中:
“取代”是指分子中的氢原子被其它不同的原子或分子所替换。
“元”是表示构成取代基主链的原子个数或构成环的骨架原子的个数。
“烷基”,是指脂肪族烷烃基团,是饱和烃基。其中,烷基可以是直链烷基或支链烷基。典型的烷基包括但不限于甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基、戊基、己基等等。
本发明中所使用的C1~Cn烷基包括C1~C2、C1~C3……C1~Cn。n是大于或等于一的整数,表示主链上的碳原子数,例如,“C1~C6烷基”是指含有1个至6个碳原子的烷基。
“烯基”,是指具有至少一个碳-碳双键的脂肪族碳氢基团。所述烯基可以是直链或支链的。
“氨基”,是指-NH3
“酰胺”是具有式-C(O)NHR或-NHC(O)R的化学结构,其中R选自烷基、杂烷基、环烷基、杂环烷基、芳基、杂芳基等。
“酰基”是具有式-C(O)R的化学结构,其中R选自烷基、杂烷基、环烷基、杂环烷基、芳基、杂芳基等。
“磺酰基”是指具有式-SO2R的化学结构,其中R选自烷基、杂烷基、环烷基、杂环烷基、芳基、杂芳基等。
“环”是指任意的共价封闭结构,其中包括如下结构:碳环(如环烷基或芳基)、杂环(如杂环烷基或杂芳基)。环可以是单环、多环或任意取代的环。典型的多环一般有二环、三环(或桥环、螺环)。
“杂烷基”是指含有杂原子的烷基,其中,杂原子包括但不限于N、O、S、P等;氨烷基、硫烷基、烷氧基等都属于杂烷基。
“杂原子”是指除了碳或氢以外的其它原子。杂原子可独立地选自于N、O、S、P或Si,但不限于此。
“芳香基”是指平面环具有离域的π电子系统且含有4n+2个π电子,n为整数。芳香基环可以由五、六、七、八、九或九个以上的原子构成,芳香基包括但不限于噻吩基、苯基、萘基、菲基等等。
“环烷基”是指单环或多环的烃基,其结构式中只含有原子和氢原子,可以是饱和的也可以是不饱和的。
“卤素”是指氟、氯、溴或碘。
本发明所述基团和化合物中所涉及的碳、氢、氧、硫、氮或F、Cl、Br、I均包括它们的同位素情况,及本发明所述基团和化合物中所涉及的碳、氢、氧、硫或氮任选进一步被一个或多个它们对应的同位素所替代,其中碳的同位素包括12C、13C和14C,氢的同位素包括氕(H)、氘(D,又叫重氢)、氚(T,又叫超重氢),氧的同位素包括16O、17O和18O,硫的同位素包括32S、33S、34S和36S,氮的同位素包括14N和15N,氟的同位素包括17F和19F,氯的同位素包括35Cl和37Cl,溴的同位素包括79Br和81Br。
在本发明中部分缩写表示的含义如下:
Me:甲基;
tBu:叔丁基。
本发明的有益效果是:
(1)本发明以萘酚和酰化的硫叶立德作为反应试剂,通过钌催化实现了萘酚C8位选择性酰甲基化以及环化反应制备萘并吡喃类化合物,为药物以及光电材料的开发奠定基础。
(2)本发明中酰化的硫叶立德结构简单易制备,价格便宜,衍生范围广,可更好地丰富萘并吡喃类化合物的结构多样性。
(3)本发明方法可通过一锅法制备,反应步骤短,操作简单,高效快捷,同时反应条件缓和,底物耐受性较好,适用范围广泛,解决了传统反应条件苛刻,操作复杂,底物局限,步骤繁琐,底物的官能团不耐受等不足。
具体实施方式
以下对本发明的技术方案进行清晰、完整地描述,显然,此处所描述的实施例仅是本发明中的一部分,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所获得的所有其他实施例,都属于本发明的保护范围。
本发明实施例中所使用的化合物2(酰化硫叶立德)可通过市售购买,也可通过现有技术合成,参考文献:
[1]S.Zhu,K.Shi,H.Zhu,Org.Lett.2020,22,1504–1509.
本发明实施例中所用的钌催化剂、碱、溶剂等都可通过商业购买获得。
本发明系列萘并吡喃类化合物的合成通式如下:
Figure BDA0002989134880000061
实施例1萘酚C8位选择性酰甲基化
一种钌催化萘酚C8位选择性酰甲基化合成方法,包括以下步骤:
将0.25mmol萘酚类底物和1.5equiv酰化硫叶立德混合,加入5mol%催化剂和2equiv碱到反应管中,20mmol%Cu(OAc)2.H2O为添加剂,在氩气保护下加入干燥二氯甲烷(2mL),100℃反应16h得混合液体。反应结束后添加水和乙酸乙酯萃取三次,合并有机层,无水Na2SO4干燥有机层,过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=30/1~5/1)分离纯化得到C8位酰甲基萘酚类化合物3。
通过本实施例方法,用带有萘酚与不同取代基的底物2a~2x制得化合物3aa~3ax,化合物后对应的百分数为产率:
Figure BDA0002989134880000071
实施例2一锅法制备萘并吡喃类化合物
将0.25mmol萘酚类底物和1.5equiv苯酰基硫叶立德混合,加入5mol%催化剂和2equiv碱到反应管中,20mmol%Cu(OAc)2.H2O为添加剂,在氩气保护下加入干燥二氯甲烷(2mL),100℃反应16h得混合液体。然后向反应体系中加入三氟甲磺酸酐(17ul),室温下继续反应6小时,反应结束后添加水和乙酸乙酯萃取三次,合并有机层,无水Na2SO4干燥有机层,过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=30/1~5/1)分离纯化得到萘并吡喃类化合物4。
通过本实施例方法,用带有萘酚与不同取代基的底物2a~2x制得如下化合物,化合物后对应的百分数为产率:
Figure BDA0002989134880000081
2-(8-hydroxynaphthalen-1-yl)-1-(4-methoxyphenyl)ethan-1-one(3aa).white solid.M.p=122–123℃.1H NMR(600MHz,CDCl3)δ=7.73(d,J=8.3Hz,1H),7.72–7.68(m,2H),7.50(d,J=8.1Hz,1H),7.43(t,J=7.4Hz,2H),7.21(d,J=6.9Hz,1H),7.05(d,J=7.6Hz,1H),6.99–6.94(m,2H),3.84(s,3H),3.48(q,J=16.3Hz,2H).13C NMR(150MHz)δ=159.94,150.60,135.87,133.81,128.49,127.02,126.83,126.45,126.21,123.71,120.87,120.78,113.88,111.46,97.85,55.46,41.93.
Figure BDA0002989134880000082
2-(8-hydroxynaphthalen-1-yl)-1-phenylethan-1-one(3ab).white solid.M.p=177–178℃.1H NMR(600MHz,DMSO)δ=7.71(d,J=8.2Hz,1H),7.67(d,J=7.4Hz,2H),7.46(d,J=8.1Hz,1H),7.43–7.37(m,4H),7.36–7.32(m,1H),7.20(d,J=7.2Hz,2H),6.95(d,J=7.3Hz,1H),3.38(q,J=16.3Hz,2H).13C NMR(150MHz)δ=151.79,144.74,133.77,130.42,128.62,128.59,127.34,126.83,126.25,125.83,123.68,121.32,120.40,111.18,98.43,41.91.
Figure BDA0002989134880000091
1-(4-(tert-butyl)phenyl)-2-(8-hydroxynaphthalen-1-yl)ethan-1-one(3ac).white solid.M.p=103–104℃.1H NMR(600MHz,DMSO)δ=7.71(d,J=8.3Hz,1H),7.58(d,J=8.4Hz,2H),7.45(d,J=8.0Hz,1H),7.43–7.38(m,4H),7.20(d,J=7.0Hz,1H),7.10(d,J=1.5Hz,1H),6.93(d,J=7.4Hz,1H),3.47(q,J=16.1Hz,2H),1.27(s,9H).13CNMR(150MHz)δ=151.90,150.98,141.82,133.76,130.53,127.34,126.82,126.00,125.80,125.31,123.63,121.33,120.32,111.12,98.42,41.81,34.81,31.67.
Figure BDA0002989134880000092
1-(4-fluorophenyl)-2-(8-hydroxynaphthalen-1-yl)ethan-1-one(3ad).whitesolid.M.p=140–141℃.1H NMR(600MHz,DMSO)δ=7.73–7.69(m,3H),7.47(d,J=8.1Hz,1H),7.41(q,J=8.0Hz,2H),7.26(d,J=1.6Hz,1H),7.26–7.19(m,3H),6.96(d,J=7.4Hz,1H),3.38(q,J=16.2Hz,2H).13C NMR(150MHz)δ=159.94,150.60,135.87,133.81,128.49,127.02,126.83,126.45,126.21,123.71,120.87,113.88,111.46,97.85,55.46,41.93.19FNMR(565MHz)δ=-113.16–-115.98(m).
Figure BDA0002989134880000093
1-(4-bromophenyl)-2-(8-hydroxynaphthalen-1-yl)ethan-1-one(3ae).whitesolid.M.p=160–161℃.1H NMR(600MHz,CDCl3)δ=7.75(d,J=8.3Hz,2H),7.64(s,4H),7.52–7.48(m,1H),7.44(q,J=7.8Hz,2H),7.32(d,J=1.7Hz,1H),7.24(d,J=6.9Hz,1H),6.98(dd,J=7.4,0.9Hz,1H),3.40(q,J=16.3Hz,2H).13C NMR(150MHz)δ=153.00,151.77,140.45,137.72,133.76,130.53,127.29,126.84,125.77,123.60,121.30,120.43,111.27,103.81,98.40,41.80.
Figure BDA0002989134880000101
2-(8-hydroxynaphthalen-1-yl)-1-(4-iodophenyl)ethan-1-one(3af).whitesolid.M.p=177–178℃.1H NMR(600MHz,DMSO)δ=7.80(d,J=8.4Hz,2H),7.74(d,J=8.3Hz,1H),7.50–7.48(m,3H),7.43(q,J=8.4Hz,2H),7.31(d,J=1.8Hz,1H),7.23(d,J=7.0Hz,1H),6.98(d,J=7.3Hz,1H).3.39(q,J=16.2Hz,2H).13C NMR(150MHz)δ=151.52,144.47,137.42,133.74,130.15,128.70,127.34,126.87,125.90,123.76,121.21,120.56,111.22,98.18,95.13,41.58.
Figure BDA0002989134880000102
2-(8-hydroxynaphthalen-1-yl)-1-(4-nitrophenyl)ethan-1-one(3ag).whitesolid.M.p=145–146℃.1H NMR(600MHz,DMSO)δ=8.32–8.22(m,2H),7.97–7.90(m,2H),7.73(d,J=8.3Hz,1H),7.54(d,J=1.8Hz,1H),7.49(d,J=8.1Hz,1H),7.46–7.38(m,2H),7.22(d,J=6.9Hz,1H),6.99(d,J=7.5Hz,1H),3.41(q,J=16.2Hz,2H).13C NMR(150MHz)δ=151.54,151.14,147.85,133.74,129.69,127.87,127.36,126.93,126.02,123.94,121.10,120.81,111.35,97.88,41.33.
Figure BDA0002989134880000103
4-(2-(8-hydroxynaphthalen-1-yl)acetyl)benzonitrile(3ah).whitesolid.M.p=177–178℃.1H NMR(600MHz,DMSO)δ=7.90–7.84(m,4H),7.73(d,J=8.3Hz,1H),7.49–7.46(m,2H),7.42(q,J=8.4Hz,2H),7.21(d,J=6.9Hz,1H),6.98(d,J=7.5Hz,1H).3.39(q,J=16.2Hz,2H).13C NMR(150MHz)δ=151.52,144.47,137.42,133.74,130.15,128.70,127.34,126.87,125.90,124.95,123.76,121.21,120.56,111.22,98.18,95.13,41.58.
Figure BDA0002989134880000111
2-(8-hydroxynaphthalen-1-yl)-1-(4-(trifluoromethyl)phenyl)ethan-1-one(3ai).whitesolid.M.p=103–104℃.1H NMR(600MHz,DMSO)δ=7.92(d,J=8.1Hz,2H),7.82(d,J=8.3Hz,2H),7.76(d,J=8.3Hz,1H),7.52(d,J=8.1Hz,1H),7.48–7.43(m,3H),7.25(d,J=6.9Hz,1H),7.01(d,J=7.5Hz,1H),3.44(q,J=16.2Hz,2H).13C NMR(150MHz)δ=151.33,149.04,133.74,129.93,129.34,129.13,127.35,127.26,126.90,125.95,125.67–125.64(d,J=3.8Hz),123.85,121.16,120.69,111.29,97.97,41.49.19F NMR(565MHz)δ=-106.97–-107.03(m).
Figure BDA0002989134880000112
2-(8-hydroxynaphthalen-1-yl)-1-(3-methoxyphenyl)ethan-1-one(3aj).white solid.M.p=131–132℃.1H NMR(600MHz,DMSO)δ=7.71(d,J=8.3Hz,1H),7.46(d,J=8.0Hz,1H),7.40(q,J=8.0Hz,2H),7.31(t,J=7.9Hz,1H),7.24(d,J=7.9Hz,1H),7.20–7.18(m,3H),6.95(d,J=6.9Hz,1H),6.91(dd,J=8.1,2.4Hz,1H),3.75(s,3H),3.38(q,J=16.1Hz,2H).13C NMR(150MHz)δ=159.56,151.77,146.33,133.76,130.43,129.74,127.33,126.84,125.81,123.67,121.30,120.42,118.53,113.92,112.15,111.19,98.32,55.62,41.78.
Figure BDA0002989134880000113
1-(3-fluorophenyl)-2-(8-hydroxynaphthalen-1-yl)ethan-1-one(3ak).whitesolid.M.p=138–139℃.1H NMR(600MHz,DMSO)δ=7.82(s,1H),7.72(d,J=8.3Hz,1H),7.66(d,J=7.8Hz,1H),7.58–7.52(m,1H),7.47(d,J=8.2Hz,1H),7.44–7.35(m,3H),7.33(d,J=1.7Hz,1H),7.20(d,J=6.9Hz,1H),6.97(d,J=7.3Hz,1H),3.38(q,J=16.1Hz,2H).13C NMR(150MHz)δ=151.40,147.30,133.73,131.54,130.99,130.08,129.13,127.34,126.88,125.90,125.49,123.79,121.97,121.18,120.63,111.28,41.52.19F NMR(565MHz)δ=-116.06(s).
Figure BDA0002989134880000121
1-(3-chlorophenyl)-2-(8-hydroxynaphthalen-1-yl)ethan-1-one(3al).whitesolid.M.p=177–178℃.1H NMR(600MHz,DMSO)δ=7.82(d,J=1.8Hz,1H),7.72(d,J=8.3Hz,1H),7.67(d,J=7.8Hz,1H),7.58–7.54(m,1H),7.47(d,J=8.1Hz,1H),7.41(q,J=8.0Hz,2H),7.37(d,J=7.9Hz,1H),7.33(d,J=1.7Hz,1H),7.20(d,J=6.9Hz,1H),6.97(d,J=7.3Hz,1H),3.36(q,J=16.1Hz,2H).13C NMR(150MHz)δ=151.40,147.31,133.73,131.54,130.97,130.07,129.14,127.33,126.88,125.90,125.48,123.79,121.97,121.18,120.63,111.28,97.77,41.54.
Figure BDA0002989134880000122
1-(3-bromophenyl)-2-(8-hydroxynaphthalen-1-yl)ethan-1-one(3am).whitesolid.M.p=106–107℃.1H NMR(600MHz,DMSO)δ=7.83(d,J=1.7Hz,1H),7.69(dd,J=29.6,8.0Hz,2H),7.58–7.54(m,1H),7.47(d,J=8.1Hz,1H),7.40(dt,J=15.8,8.1Hz,3H),7.34(d,J=1.7Hz,1H),7.20(d,J=6.8Hz,1H),6.97(d,J=7.5Hz,1H),3.39(q,J=16.1Hz,2H).13C NMR(150MHz)δ=151.41,147.32,133.74,131.54,130.98,130.08,129.14,127.34,126.88,125.91,125.49,123.80,121.98,121.19,120.64,111.29,97.78,41.54.
Figure BDA0002989134880000123
1-(3,4-dimethoxyphenyl)-2-(8-hydroxynaphthalen-1-yl)ethan-1-one(3an).white solid.M.p=134–135℃.1H NMR(600MHz,DMSO)δ=7.70(d,J=8.3Hz,1H),7.44(d,J=8.1Hz,1H),7.40(dt,J=11.0,7.7Hz,2H),7.22(d,J=1.9Hz,1H),7.18(m,2H),7.08(s,1H),6.94(d,J=8.2Hz,2H),3.39(q,J=16.1Hz,2H).13C NMR(150MHz)δ=161.91,156.28,155.59,152.18,139.28,135.59,132.28,129.17,125.55,126.55,123.86,120.15,118.05,118.38,115.92,110.29,43.29.
Figure BDA0002989134880000131
1-(3-bromo-4-methoxyphenyl)-2-(8-hydroxynaphthalen-1-yl)ethan-1-one(3ao).white solid.M.p=148–149℃.1H NMR(600MHz,DMSO)δ=7.80(d,J=2.4Hz,1H),7.70(d,J=8.3Hz,1H),7.60(dd,J=8.4,2.1Hz,1H),7.45(d,J=8.1Hz,1H),7.37–7.36(m,2H),7.22(d,J=1.8Hz,1H),7.19(d,J=6.9Hz,1H),7.12(d,J=8.8Hz,1H),6.94(d,J=7.6Hz,1H),3.83(s,3H).2.94(q,J=16.2Hz,2H).13C NMR(150MHz)δ=155.95,152.89,139.57,138.45,131.29,128.17,125.22,123.43,122.44,120.19,119.96,115.67,114.29,112.81,111.19,110.73,98.29,56.99,43.42.
Figure BDA0002989134880000132
1-(2-fluoro-4-methoxyphenyl)-2-(8-hydroxynaphthalen-1-yl)ethan-1-one(3ap).white solid.M.p=140–141℃.1H NMR(600MHz,DMSO)δ=7.70(d,J=8.3Hz,1H),7.62(t,J=9.1Hz,1H),7.45(d,J=8.0Hz,1H),7.42–7.36(m,2H),7.29(d,J=1.9Hz,1H),7.22–7.19(m,1H),6.93(d,J=7.6Hz,1H),6.83(dd,J=13.4,2.4Hz,1H),6.78(dd,J=8.8,2.5Hz,1H),3.75(s,3H),3.38(q,J=16.1Hz,2H).13C NMR(150MHz)δ=158.26,159.18,155.28,149.87,136.66,132.01,129.19,128.63,127.59,126.39,124.95,122.28,119.87,111.74,110.95,101.28,98.36,57.21,45.19.19F NMR(565MHz)δ=-110.42(s).
Figure BDA0002989134880000133
1-(benzo[d][1,3]dioxol-5-yl)-2-(8-hydroxynaphthalen-1-yl)ethan-1-one(3aq).white solid.M.p=159–160℃.1H NMR(600MHz,DMSO)δ=7.69(d,J=8.3Hz,1H),7.44(d,J=8.1Hz,1H),7.42–7.36(m,1H),7.19–7.17(m,1H),7.15(t,J=2.2Hz,2H),7.10(d,J=1.9Hz,1H),6.92(d,J=7.6Hz,1H),6.90(d,J=8.0Hz,1H),6.00(d,J=2.7Hz,2H),3.21(q,J=16.1Hz,2H).13C NMR(150MHz)δ=160.55,155.69,151.85,149.84,136.85,132.10,131.58,129.18,126.54,125.96,124.16,122.83,120.85,115.36,110.26,109.54,100.69,45.22.
Figure BDA0002989134880000141
2-(8-hydroxynaphthalen-1-yl)-1-(3,4,5-trimethoxyphenyl)ethan-1-one(3ar).white solid.M.p=139–140℃.1H NMR(600MHz,DMSO)δ=7.71(d,J=8.3Hz,1H),7.46(d,J=8.1Hz,1H),7.44–7.38(m,2H),7.19(d,J=6.6Hz,1H),7.13(d,J=1.9Hz,1H),6.98–6.92(m,3H),3.78(s,6H),3.66(s,3H),3.34(q,J=16.3Hz,2H).13C NMR(150MHz)δ=160.29,158.19,155.63,145.27,138.74,135.49,132.46,131.28,128.25,125.66,123.40,122.50,120.98,111.44,108.29,61.80,58.42,45.19.
Figure BDA0002989134880000142
2-(8-hydroxynaphthalen-1-yl)-1-(naphthalen-1-yl)ethan-1-one(3as).white solid.M.p=209–210℃.1H NMR(600MHz,DMSO)δ=8.81(dd,J=7.5,1.4Hz,1H),8.35(s,1H),8.26(dd,J=7.5,1.3Hz,1H),7.93(d,J=7.7Hz,2H),7.85–7.59(m,3H),7.56–7.14(m,4H),6.92(dd,J=7.4,1.5Hz,1H),6.28(dd,J=7.5,1.4Hz,1H),3.12(q,J=16.2Hz,2H).13C NMR(150MHz)δ=162.18,154.47,136.58,135.08,133.28,132.67,132.00,131.44,130.46,128.50,127.52,126.85,124.40,120.50,112.29,48.34.
Figure BDA0002989134880000143
1-(furan-2-yl)-2-(8-hydroxynaphthalen-1-yl)ethan-1-one(3at).whitesolid.M.p=118–119℃.1H NMR(600MHz,DMSO)δ=7.96(s,1H),7.63(s,1H),7.46–7.42(m,1H),7.34–7.27(m,2H),7.23(d,J=6.9Hz,1H),6.91(d,J=7.4Hz,1H),6.74–6.66(m,2H),6.45(d,J=3.2Hz,1H),3.15(q,J=16.2Hz,2H).13C NMR(150MHz)δ=159.72,156.18,156.09,149.28,139.56,135.07,136.17,128.15,127.29,126.18,126.06,121.15,114.22,110.84,106.18,46.28.
Figure BDA0002989134880000151
2-(8-hydroxynaphthalen-1-yl)-1-(thiophen-2-yl)ethan-1-one(3au).whitesolid.M.p=132–133℃.1H NMR(600MHz,DMSO)δ=8.04(d,J=4.3Hz,1H),7.93(d,J=4.7Hz,1H),7.68(d,J=8.1Hz,1H),7.58(d,J=0.9Hz,1H),7.46(dd,J=8.5,4.3Hz,2H),7.27–7.21(m,1H),6.92(d,J=7.3Hz,1H),6.69(d,J=7.5Hz,1H).3.25(q,J=16.1Hz,2H).13C NMR(150MHz)δ=159.58,154.37,153.29,148.17,139.38,133.16,131.46,130.29,129.89,127.59,126.14,125.75,124.19,123.55,45.19.
Figure BDA0002989134880000152
1-(8-hydroxynaphthalen-1-yl)-3-methyl-3-phenylbutan-2-one(3av).whitesolid.M.p=73–74℃.1H NMR(600MHz,DMSO)δ=7.64–7.57(m,3H),7.37(d,J=7.2Hz,1H),7.33(q,J=7.8Hz,2H),7.27(t,J=7.7Hz,2H),7.16(t,J=7.3Hz,2H),7.05(d,J=6.9Hz,1H),6.89–6.85(m,1H),6.06(d,J=1.2Hz,1H),2.94(q,J=16.2Hz,2H),1.55(d,J=18.5Hz,6H).13C NMR(150MHz)δ=151.29,146.15,133.61,130.16,128.79,127.95,127.18,126.75,126.47,125.43,124.08,121.10,120.02,110.90,100.92,46.72,34.41,24.30,24.11.
Figure BDA0002989134880000153
1-(8-hydroxynaphthalen-1-yl)-3,3-dimethylbutan-2-one(3aw).whitesolid.M.p=112–113℃.1H NMR(600MHz,DMSO)δ=7.66(d,J=8.3Hz,1H),7.43–7.36(m,2H),7.34(t,J=7.8Hz,1H),7.18(d,J=6.8Hz,1H),6.82(d,J=7.4Hz,1H),5.76(s,1H),3.21(q,J=16.1Hz,2H),1.11(s,9H).13C NMR(150MHz)δ=151.71,133.70,130.68,127.18,126.75,125.40,124.15,121.42,119.87,110.82,101.54,39.38,33.57,25.44.
Figure BDA0002989134880000154
1-(adamantan-2-yl)-2-(8-hydroxynaphthalen-1-yl)ethan-1-one(3ax).whitesolid.M.p=153–154℃.1H NMR(600MHz,DMSO)δ=7.70(d,J=8.3Hz,1H),7.42(t,J=7.3Hz,2H),7.37(t,J=7.8Hz,1H),7.21(d,J=6.9Hz,1H),6.85(d,J=7.5Hz,1H),5.72(d,J=1.2Hz,1H),3.19(q,J=16.1Hz,2H),1.88(s,7H),1.71(q,J=12Hz,7H).13C NMR(150MHz)δ=151.73,133.69,130.78,127.16,126.72,125.34,124.20,121.54,119.80,110.81,101.08,40.55,37.25,36.01,32.71,28.39.
Figure BDA0002989134880000161
2-(4-methoxyphenyl)benzo[de]chromene(4aa).yellow solid.M.p=120–121℃.1H NMR(600MHz,CDCl3)δ=7.75–7.67(m,2H),δ7.32(d,J=8.3Hz,1H),7.28(t,J=7.9Hz,1H),7.24–7.18(m,2H),6.99–6.90(m,2H),6.85(d,J=7.5Hz,1H),6.75(d,J=6.9Hz,1H),6.39(s,1H),3.85(s,3H).13C NMR(150MHz)δ=160.35,152.98,151.99,134.77,130.26,127.86,127.41,126.08,125.70,123.02,122.96,119.30,115.41,113.83,106.97,101.41,55.31.
Figure BDA0002989134880000162
2-(4-fluorophenyl)benzo[de]chromene(4ab).yellow solid.M.p=91–92℃.1HNMR(600MHz,CDCl3)δ=7.75(dd,J=8.7,5.4Hz,2H),7.34(d,J=8.4Hz,1H),7.28(t,J=7.9Hz,1H),7.22(dd,J=14.3,7.4Hz,2H),7.11(t,J=8.6Hz,2H),6.84(d,J=7.5Hz,1H),6.76(d,J=7.0Hz,1H),6.42(s,1H).13C NMR(150MHz)δ=164.03,162.38,152.80,151.19,134.75,129.77,129.31,127.86,127.49,126.53(d,J=8.1Hz),123.51,123.06,119.52,115.91,115.58,115.44,107.11,102.77.19F NMR(565MHz)δ=-110.09(s).
Figure BDA0002989134880000163
2-(4-chlorophenyl)benzo[de]chromene(4ac).yellow solid.M.p=126–127℃.1H NMR(600MHz,CDCl3)δ=7.68(d,J=8.5Hz,2H),7.38(d,J=8.5Hz,2H),7.34(d,J=8.4Hz,1H),7.28(t,J=7.9Hz,1H),7.22(m,2H),6.83(d,J=7.5Hz,1H),6.76(d,J=7.0Hz,1H),6.45(s,1H).13C NMR(150MHz)δ=152.85,151.10,135.03,134.87,131.66,129.73,128.82,127.98,127.66,125.97,123.86,123.26,119.70,116.28,107.30,103.49.
Figure BDA0002989134880000171
2-(4-iodophenyl)benzo[de]chromene(4ad).yellow solid.M.p=129–130℃.1HNMR(600MHz,CDCl3)δ=7.75(d,J=8.4Hz,2H),7.49(d,J=8.4Hz,2H),7.34(d,J=8.4Hz,1H),7.28(t,J=7.9Hz,1H),7.24–7.19(m,2H),6.83(d,J=7.6Hz,1H),6.77(d,J=7.0Hz,1H),6.49(s,1H).13C NMR(150MHz)δ=152.83,151.24,137.72,134.87,132.71,129.67,127.98,127.66,126.32,123.94,123.30,119.70,116.35,107.32,103.61,95.07.
Figure BDA0002989134880000172
4-(benzo[de]chromen-2-yl)benzonitrile(4ae).yellow solid.M.p=165–166℃.1H NMR(600MHz,CDCl3)δ=7.84(d,J=8.3Hz,2H),7.68(d,J=8.3Hz,2H),7.39(d,J=8.4Hz,1H),7.30(t,J=7.9Hz,1H),7.26–7.21(m,2H),6.85(d,J=7.5Hz,1H),6.82(d,J=7.0Hz,1H),6.59(s,1H).13C NMR(150MHz)δ=152.42,149.95,137.11,134.69,132.27,128.92,127.86,127.66,124.86,124.62,123.19,119.85,118.64,117.03,112.14,107.38,105.84.
Figure BDA0002989134880000173
2-(4-(trifluoromethyl)phenyl)benzo[de]chromene(4af).yellow solid.M.p=84–85℃.1H NMR(600MHz,CDCl3)δ=7.87(d,J=8.1Hz,2H),7.67(d,J=8.1Hz,2H),7.37(d,J=8.4Hz,1H),7.30(t,J=7.9Hz,1H),7.24–7.20(m,2H),6.86(d,J=7.5Hz,1H),6.81(d,J=7.0Hz,1H),6.58(s,1H).13C NMR(150MHz)δ=152.75,150.69,136.52,134.86,131.37–130.14(m),129.38,127.98,127.73,125.58,124.88,124.34,123.35,123.27–123.04(m),119.84,116.74,107.43,104.96.19F NMR(565MHz)δ=-62.51(s).
Figure BDA0002989134880000181
2-([1,1'-biphenyl]-4-yl)benzo[de]chromene(4ag).yellow solid.M.p=158–159℃.1H NMR(600MHz,CDCl3)δ=7.85(d,J=8.3Hz,2H),7.67(d,J=8.3 Hz,2H),7.65(d,J=7.5Hz,2H),7.48(t,J=7.6Hz,2H),7.42–7.34(m,2H),7.31(t,J=7.9Hz,1H),7.26–7.22(m,2H),6.89(d,J=7.5Hz,1H),6.79(d,J=6.9Hz,1H),6.55(s,1H).13C NMR(150MHz)δ=153.09,151.93,141.93,140.44,134.94,132.10,130.12,129.00,128.02,127.77,127.68,127.27,127.15,125.17,123.64,123.38,119.58,116.10,107.30,103.23.
Figure BDA0002989134880000182
2-(m-tolyl)benzo[de]chromene(4ah).yellow solid.M.p=92–93℃.1H NMR(600MHz,CDCl3)δ=7.62–7.56(m,2H),7.36–7.31(m,2H),7.30(t,J=7.9Hz,1H),7.24(d,J=2.9Hz,1H),7.23–7.20(m,2H),6.87(d,J=7.6Hz,1H),6.78(d,J=7.0 Hz,1H),6.50(s,1H),2.44(s,3H).13C NMR(150MHz)δ=153.16,152.38,138.27,134.94,133.21,130.22,130.10,128.54,128.00,127.64,125.39,123.50,123.38,121.98,119.49,115.94,107.24,103.10,21.68.
Figure BDA0002989134880000183
2-(3-methoxyphenyl)benzo[de]chromene(4ai).yellow solid.M.p=131–132℃.1H NMR(600MHz,CDCl3)δ=7.35(m,4H),7.29(t,J=7.9Hz,1H),7.22(m,2H),6.94(d,J=6.6Hz,1H),6.86(d,J=7.6Hz,1H),6.78(d,J=7.0Hz,1H),6.50(s,1H),3.88(s,3H).13CNMR(150MHz)δ=159.84,153.06,151.99,134.91,134.68,130.04,129.65,127.99,127.65,123.65,123.38,119.54,117.30,116.08,114.78,110.42,107.27,103.50,55.49.
Figure BDA0002989134880000191
2-(3-bromophenyl)benzo[de]chromene(4aj).yellow solid.M.p=88–89℃.1HNMR(600MHz,CDCl3)δ=7.91(s,1H),7.68(d,J=7.8Hz,1H),7.50(d,J=7.8Hz,1H),7.35(d,J=8.4Hz,1H),7.28(t,J=7.2Hz,2H),7.22(m,2H),6.85(d,J=7.6Hz,1H),6.78(d,J=7.0Hz,1H),6.48(s,1H).13C NMR(150MHz)δ=152.79,150.60,135.23,134.85,132.06,130.11,129.55,127.96,127.70,124.06,123.32,123.22,122.88,119.74,116.49,107.39,104.17.
Figure BDA0002989134880000192
2-(2-fluorophenyl)benzo[de]chromene(4ak).yellow solid.M.p=74–75℃.1HNMR(600MHz,CDCl3)δ=7.86(td,J=7.9,1.4Hz,1H),7.38–7.31(m,2H),7.28(t,J=7.9Hz,1H),7.22(m,3H),7.14(dd,J=12.1,8.2Hz,1H),6.81(dd,J=17.1,7.3Hz,2H),6.72(s,1H).13C NMR(150MHz)δ=160.93,159.26,152.94,146.89,134.83,130.31(d,J=8.8Hz),129.78,127.96(d,J=12.6Hz),127.61,124.33(d,J=3.5Hz),124.00,123.27,121.46(d,J=10.0Hz),119.54,116.67,116.37(d,J=23.0Hz),108.55(d,J=14.3Hz),107.14.19F NMR(565MHz)δ=-111.748(s).
Figure BDA0002989134880000193
2-(o-tolyl)benzo[de]chromene(4al).yellow solid.M.p=112–113℃.1H NMR(600MHz,CDCl3)δ=7.48(d,J=7.5Hz,1H),7.35(d,J=8.4Hz,1H),7.31(d,J=7.2Hz,1H),7.27(d,J=7.8Hz,2H),7.24–7.19(m,3H),6.74(dd,J=21.1,7.2Hz,2H),6.09(s,1H),2.52(s,3H).13C NMR(150MHz)δ=154.45,153.34,136.75,134.98,134.21,130.97,130.26,129.43,128.81,127.98,127.65,126.01,123.58,123.24,119.55,115.68,107.17,106.87,20.74.
Figure BDA0002989134880000201
2-(4-bromo-3-methoxyphenyl)benzo[de]chromene(4am).yellow solid.M.p=124–125℃.1H NMR(600MHz,CDCl3)δ=7.96(d,J=1.8Hz,1H),7.68(dd,J=8.6,1.8Hz,1H),7.32(d,J=8.4Hz,1H),7.28(t,J=7.9Hz,1H),7.24–7.18(m,2H),6.92(d,J=8.7Hz,1H),6.84(d,J=7.6Hz,1H),6.75(d,J=6.9Hz,1H),6.38(s,1H),3.93(s,3H).13C NMR(150MHz)δ=156.56,152.89,150.68,134.87,129.93,129.76,127.99,127.61,127.17,125.08,123.53,123.15,119.64,115.95,111.94,111.63,107.26,102.42,56.46.
Figure BDA0002989134880000202
2-(3,4-dimethoxyphenyl)benzo[de]chromene(4an).yellow solid.M.p=99–100℃.1H NMR(600MHz,CDCl3)δ=7.37(dd,J=8.3,1.9Hz,1H),7.32(d,J=8.4Hz,1H),7.30–7.25(m,2H),7.24–7.17(m,2H),6.90(d,J=8.4Hz,1H),6.85(d,J=7.5Hz,1H),6.75(d,J=7.0Hz,1H),6.39(s,1H),3.97(s,3H),3.92(s,3H).13C NMR(150MHz)δ=152.95,151.96,149.94,148.80,134.78,130.16,127.88,127.42,126.01,123.07,123.03,119.37,117.74,115.48,110.82,107.65,107.01,101.80,55.93(d,J=2.8Hz).
Figure BDA0002989134880000203
2-(3,4,5-trimethoxyphenyl)benzo[de]chromene(4ao).yellow solid.M.p=135–136℃.1H NMR(600MHz,CDCl3)δ=7.33(d,J=8.4Hz,1H),7.28(t,J=7.9Hz,1H),7.24–7.19(m,2H),6.98(s,2H),6.86(d,J=7.5Hz,1H),6.77(d,J=6.9Hz,1H),6.41(s,1H),3.94(s,6H),3.90(s,3H).13C NMR(150MHz)δ=153.35,153.01,152.03,139.20,134.91,130.03,128.90,128.02,127.60,123.55,123.22,119.63,115.93,107.25,103.00,102.17,61.10,56.34.
Figure BDA0002989134880000211
2-(furan-2-yl)benzo[de]chromene(4ap).yellow solid.M.p=89–90℃.1H NMR(600MHz,CDCl3)δ=7.46(s,1H),7.33(d,J=8.4Hz,1H),7.27(d,J=7.9Hz,1H),7.21(dd,J=14.3,7.4Hz,2H),6.79(dd,J=20.0,7.2Hz,2H),6.74(d,J=3.3Hz,1H),6.50(dd,J=3.2,1.5Hz,1H),6.46(s,1H).13C NMR(150MHz)δ=152.48,148.08,144.93,143.22,134.90,129.35,127.94,127.54,123.67,123.22,119.78,116.33,111.76,108.29,107.37,101.80.
Figure BDA0002989134880000212
2-(octahydro-2,5-methanopentalen-7-yl)benzo[de]chromene(4aq).yellowsolid.M.p=110–111℃.1H NMR(600MHz,CDCl3)δ=7.26(d,J=8.2Hz,1H),7.24–7.21(m,1H),7.18–7.14(m,2H),5.75(s,1H),2.07(s,3H),1.90(m,6H),1.76(q,J=12.1Hz,6H).13CNMR(150MHz)δ=163.69,153.62,134.95,130.75,127.94,127.43,123.23,122.59,118.91,114.88,106.63,99.86,39.73,36.97,36.85,28.28.
Figure BDA0002989134880000213
2-(4-methoxyphenyl)-9-methylbenzo[de]chromene(4ba).yellow solid.M.p=80–81℃.1H NMR(600MHz,CDCl3)δ=7.74(d,J=8.7Hz,2H),7.28(d,J=8.3Hz,1H),7.16(dt,J=15.5,8.1Hz,3H),6.96(d,J=8.7Hz,2H),6.73(d,J=6.9Hz,1H),6.41(s,1H),3.86(s,3H),2.36(s,3H).13C NMR(150MHz)δ=160.45,151.91,149.99,133.31,130.33,129.98,126.92,126.19,126.05,123.12,122.98,118.79,116.17,115.47,114.03,101.45,55.48,15.38.
Figure BDA0002989134880000221
7-bromo-2-(4-methoxyphenyl)benzo[de]chromene(4ca).yellow solid.M.p=159–160℃.1H NMR(600MHz,CDCl3)δ=7.70(d,J=8.8Hz,2H),7.59(d,J=8.6Hz,1H),7.55(d,J=8.2Hz,1H),7.34(dd,J=8.3,7.3Hz,1H),6.94(d,J=8.8Hz,2H),6.83(d,J=7.1Hz,1H),6.75(d,J=8.2Hz,1H),6.44(s,1H),3.85(s,3H).13C NMR(150MHz)δ=160.73,152.69,152.25,133.03,131.01,130.75,129.39,126.31,125.39,123.91,122.52,116.51,114.07,112.12,107.99,101.26,55.48.
Figure BDA0002989134880000222
5-bromo-2-(4-methoxyphenyl)benzo[de]chromene(4da).yellow solid.M.p=137–138℃.1H NMR(600MHz,CDCl3)δ=7.71(d,J=8.8Hz,2H),7.44(d,J=1.6Hz,1H),7.29(t,J=7.9Hz,1H),7.12(d,J=8.2Hz,1H),6.95(d,J=8.9Hz,2H),6.86(d,J=7.6Hz,1H),6.83(d,J=1.4Hz,1H),6.33(s,1H),3.86(s,3H).13C NMR(150MHz)δ=161.89,153.43,153.00,135.94,132.57,128.64,126.46,125.37,124.71,122.45,121.57,118.68,118.29,114.09,107.70,100.42,55.49.
Figure BDA0002989134880000223
4-(4-methoxyphenyl)phenanthro[3,4,5-defg]chromene(4ea).yellowsolid.M.p=150–151℃.1H NMR(600MHz,CDCl3)δ=7.91(d,J=8.4Hz,1H),7.79–7.72(m,7H),7.70(d,J=7.4Hz,1H),7.44(d,J=8.3Hz,1H),7.10(s,1H),6.96(d,J=8.7Hz,2H),6.53(s,1H),3.85(s,3H).13C NMR(150MHz)δ=160.59,152.50,150.46,134.06,132.41,128.95,126.85,126.66,126.56,126.31,126.04,125.99,125.87,125.62,125.27,122.14,121.92,118.45,114.12,114.04,112.34,102.50,102.50,55.47.
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。

Claims (10)

1.化合物3的制备方法,其特征在于,包含以下内容:在惰性气体和/或氮气气氛下,将化合物1、化合物2、钌催化剂、添加剂、碱、溶剂混合:
Figure FDA0002989134870000011
所述钌催化剂选自钌化合物和/或钌络合物;
所述添加剂选自铜盐或铜的氧化物;
R1选自非取代或取代的烷基、非取代或取代的杂烷基、非取代或取代的环烷基、非取代或取代的杂环烷基、非取代或取代的芳基、非取代或取代的杂芳基;
R3选自卤素、硝基、羟基、巯基、氨基、氰基、酰胺基、酰基、酯基、磺酰基、非取代或取代的烷基、非取代或取代的杂烷基、非取代或取代的环烷基、非取代或取代的杂环烷基、非取代或取代的芳基、非取代或取代的杂芳基;
R1、R3中的取代基选自卤素、硝基、羟基、巯基、氨基、氰基、酰胺基、酰基、酯基、磺酰基、烷基、杂烷基、环烷基、杂环烷基、芳基、杂芳基,或两个相邻的取代基共同组成非取代或取代的烷基、非取代或取代的杂烷基;
n选自0、1、2、3、4。
2.根据权利要求1所述制备方法,其特征在于,所述钌催化剂选自为[RuCl2(p-cymene)]2、CpRuCl(PPh3)2、RuCl3、RuCl2(PPh3)3中的一种或几种,优选[RuCl2(p-cymene)]2
进一步地,所述钌催化剂的摩尔用量为化合物1摩尔用量的1.0%~20.0%,优选1.0%~10.0%,优选2.0%~7.0%,更优选为5.0%。
3.根据权利要求1所述制备方法,其特征在于,所述添加剂选自Cu(OAc)2、Cu(OAc)2·H2O、Cu(OAc)、CuCl2、CuO、Cu2O中的一种或几种,优选Cu(OAc)2和/或Cu(OAc)2·H2O;
进一步地,所述添加剂的摩尔用量为化合物1摩尔用量的1.0%~20.0%,优选1.0%~10.0%,优选2.0%~7.0%,更优选为5.0%。
4.根据权利要求1所述制备方法,其特征在于,所述碱选自无机碱;进一步地,所述碱选自KOAc、NaOAc、K2CO3、Na2CO3、Cs2CO3、KHCO3、NaHCO3、K3PO4、Na3PO4、K2HPO4、Na2HPO4、KH2PO4、NaH2PO4中的一种或几种,优选KOAc;
进一步地,所述碱的摩尔用量为化合物1摩尔用量的1~5倍,优选1~3倍,更优选为2倍。
5.根据权利要求1所述制备方法,其特征在于,所述溶剂选自二氯甲烷、二氯乙烷、四氢呋喃、甲苯、三氟甲苯中的一种或几种,优选二氯甲烷;
进一步地,所述溶剂的用量为,化合物1:溶剂的料液比为1mmol:5~15mL,优选为1mmol:5~10mL,更优选为1mmol:8mL。
6.根据权利要求1所述制备方法,其特征在于,所述反应的温度为80℃~120℃,优选100℃。
7.根据权利要求1所述制备方法,其特征在于,所述化合物2的摩尔用量为化合物1摩尔用量的1~5倍,优选1~3倍,更优选为1.5倍。
8.根据权利要求1所述制备方法,其特征在于,R1选自非取代或取代的C1~C12烷基、非取代或取代的2~11元杂烷基、非取代或取代的C1~C12环烷基、非取代或取代的2~11元杂环烷基、非取代或取代的6~10元芳基、非取代或取代的5~10元杂芳基;
R3选自卤素、硝基、羟基、氰基、酰胺基、酰基、酯基、非取代或取代的烷基、非取代或取代的杂烷基、非取代或取代的环烷基、非取代或取代的杂环烷基、非取代或取代的芳基、非取代或取代的杂芳基;
R1、R3中的取代基选自卤素、硝基、羟基、氨基、氰基、酰胺基、酰基、酯基、烷基、杂烷基、环烷基、杂环烷基、芳基、杂芳基,或两个相邻的取代基共同组成非取代或取代的烷基、非取代或取代的杂烷基;
进一步地,R1选自非取代或取代的C1~C6烷基、非取代或取代的2~5元杂烷基、非取代或取代的C1~C12环烷基、非取代或取代的2~11元杂环烷基、非取代或取代的6~10元芳基、非取代或取代的5元杂芳基;
R3选自卤素、非取代或取代的C1~C6烷基、非取代或取代的2~5元杂烷基、非取代或取代的C1~C6环烷基、非取代或取代的2~5元杂环烷基;
R1、R3中的取代基选自卤素、硝基、羟基、氨基、氰基、酰胺基、酰基、酯基、烷基、杂烷基、环烷基、杂环烷基、芳基、杂芳基,或两个相邻的取代基共同组成非取代或取代的烷基、非取代或取代的杂烷基;
进一步地,R1选自非取代或取代的C1~C6烷基、非取代或取代的C1~C12环烷基、非取代或取代的苯基、非取代或取代的萘基、非取代或取代的噻吩基、非取代或取代的呋喃基;
R3选自卤素、非取代或取代的C1~C6烷基;
R1、R3中的取代基选自卤素、硝基、氰基、烷基、烷氧基、芳基,或两个相邻的取代基共同组成非取代或取代的氧杂烷基;n选自0、1、2;
进一步地,R1选自非取代或取代的C1~C6烷基、非取代或取代的C1~C12环烷基、非取代或取代的苯基、非取代或取代的萘基、非取代或取代的噻吩基、非取代或取代的呋喃基;
R3选自卤素、非取代或取代的C1~C3烷基;
R1、R3中的取代基选自卤素、硝基、氰基、烷基、三氟甲基、烷氧基、苯基、乙烯基,或两个相邻的取代基共同组成非取代或取代的
Figure FDA0002989134870000031
n选自0、1;
更进一步地,所述R1选自如下基团:
Figure FDA0002989134870000032
R3选自Br、甲基。
9.一种化合物4的制备方法,其特征在于,向权利要求1~8任一项所述方法反应后的反应体系中加入三氟甲磺酸酐:
Figure FDA0002989134870000033
10.根据权利要求9所述制备方法,其特征在于,所述三氟甲磺酸酐的摩尔用量为化合物1摩尔用量的0.2~2倍,优选0.2~1倍,更优选为0.3~0.5倍。
CN202110309305.0A 2021-03-23 2021-03-23 一种钌催化制备萘并吡喃类化合物的方法 Active CN113045530B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110309305.0A CN113045530B (zh) 2021-03-23 2021-03-23 一种钌催化制备萘并吡喃类化合物的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110309305.0A CN113045530B (zh) 2021-03-23 2021-03-23 一种钌催化制备萘并吡喃类化合物的方法

Publications (2)

Publication Number Publication Date
CN113045530A true CN113045530A (zh) 2021-06-29
CN113045530B CN113045530B (zh) 2024-04-09

Family

ID=76514605

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110309305.0A Active CN113045530B (zh) 2021-03-23 2021-03-23 一种钌催化制备萘并吡喃类化合物的方法

Country Status (1)

Country Link
CN (1) CN113045530B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115286609A (zh) * 2022-08-09 2022-11-04 浙江理工大学 一种2-三氟甲基取代的二氢苯并色烯的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110577529A (zh) * 2019-10-10 2019-12-17 常州工程职业技术学院 N-(杂)芳基-7-氮杂吲哚的α-酮类化合物及制备方法
CN112239424A (zh) * 2019-12-18 2021-01-19 温州医科大学 一种马兜铃生物碱及其中间体的制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110577529A (zh) * 2019-10-10 2019-12-17 常州工程职业技术学院 N-(杂)芳基-7-氮杂吲哚的α-酮类化合物及制备方法
CN112239424A (zh) * 2019-12-18 2021-01-19 温州医科大学 一种马兜铃生物碱及其中间体的制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FLEISCHHACKER, W.等: "Heterocyclen-anellierte Naphthaline aus Thebain. 1", LIEBIGS ANNALEN DER CHEMIE., vol. 5, pages 844 - 851 *
PIDIYARA KARISHMA等: "Ruthenium Catalyzed C@H Acylmethylation of N-Arylphthalazine-1, 4-diones with α-Carbonyl Sulfoxonium Ylides: Highway to Diversely Functionalized Phthalazino-fused Cinnolines", CHEM.ASIAN J., vol. 14, pages 4274 - 4288 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115286609A (zh) * 2022-08-09 2022-11-04 浙江理工大学 一种2-三氟甲基取代的二氢苯并色烯的制备方法
CN115286609B (zh) * 2022-08-09 2023-12-19 浙江理工大学 一种2-三氟甲基取代的二氢苯并色烯的制备方法

Also Published As

Publication number Publication date
CN113045530B (zh) 2024-04-09

Similar Documents

Publication Publication Date Title
Arcadi et al. Palladium-catalysed coupling of aryl and vinyl triflates or halides with 2-ethynylaniline: an efficient route to functionalized 2-substituted indoles
Wang et al. Visible light-enabled iron-catalyzed selenocyclization of N-methoxy-2-alkynylbenzamide
CN105801575A (zh) 一种咪唑并[1,2-a]吡啶的合成方法
CN112675919A (zh) 氮杂环卡宾基混配型镍(II)配合物在合成α-苄基苯并呋喃类化合物中的应用
CN113045530B (zh) 一种钌催化制备萘并吡喃类化合物的方法
CN112209905A (zh) 一种多取代α-烯基内酯类化合物、其制备方法及应用
CN111592507A (zh) 一种绿色简单制备多取代呋喃的新方法
CN108912076B (zh) 一种苯并氧杂环化合物的合成方法
EP1731509B1 (en) Process for producing nitrogenous 5-membered cyclic compound
CN114605361A (zh) 一种合成γ-羟基-γ-全氟甲基丁烯内酯类化合物的方法
CN111662147B (zh) 制备二炔及其类似物的方法
CN112812084B (zh) 一种苯并呋喃类化合物的合成方法
CN109265403B (zh) 一种苯并咪唑及其衍生物的合成方法
CN109369515B (zh) 一种不饱和双键取代的碳环衍生物的合成方法
CN111559993A (zh) 一种呋喃甲醇类化合物的制备方法
CN111303096A (zh) 一种多取代1,3-二氢萘并[2,3-c]呋喃衍生物的合成方法
CN112625020A (zh) 一种铑催化碳氢键活化反应合成异香豆素衍生物
Zhang et al. Enantioselective fluorination of β-keto esters using a PEG-bound urea-containing chiral quaternary ammonium salt catalyst
CN115466171B (zh) 一种2,3-二氢-1H-环戊烯并[a]萘衍生物的制备方法
CN112126941B (zh) 一种多取代10-羟基菲衍生物及其制备方法
CN114805289B (zh) 一种1,4-氧硫杂-3,5-二醛基环己二烯化合物的制备方法
CN115057848B (zh) 一种轴手性异吡喃酮-吲哚衍生物及其合成方法
KR101006737B1 (ko) 구리 촉매를 이용한 2-술포닐이미노인돌린 제조방법
CN113620795B (zh) 苯并环庚烯酮类化合物的合成方法
CN107417583A (zh) 利用非金属催化剂选择性合成烯丙基砜化合物的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant